相关实验视频

Updated: Jul 16, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

免疫检查点抑制剂在广泛阶段小细胞肺癌中在社区环境中实际使用

Ke Zu¹, Ashwini Arunachalam¹, Andriana Hohlbauch²

¹Merck & Co., Inc., Rahway, NJ 07065, USA.

|September 11, 2023

概括

现实数据显示,免疫检查点抑制剂 (ICI) 在广泛的小细胞肺癌 (ES-SCLC) 中的使用正在增加. 然而,仍然存在重大未满足的需求,特别是关于ICI在这个患者群体中的再挑战策略.

科学领域:

在瘤学瘤学.
肺部病理学肺部病理学
药理学药理学是指药理学的学科.

背景情况:

免疫检查点抑制剂 (ICI) 已经改变了扩散阶段小细胞肺癌 (ES-SCLC) 的治疗模式.
了解ICI引入后的现实世界治疗模式对于优化患者护理至关重要.
在ES-SCLC管理中仍然存在重大未满足的需求,特别是关于连续ICI使用.

研究的目的:

分析ES-SCLC成年患者在ICI可供前线治疗后的现实世界治疗模式.
调查ICI在复发/渐进和新的ES-SCLC环境中的使用情况.
为了评估ICI再挑战和再治疗策略在随后的治疗线.

主要方法:

对开始一线 (1L) 系统治疗的ES-SCLC成年患者的回顾性分析.
从电子健康记录中提取的数据.
在第一线 (1L),第二线 (2L) 和第三线 (3L) 设置中检查治疗模式.

主要成果:

在复发/进展的ES-SCLC中,以为基础的化疗在1L (81.1%) 中占主导地位,而ICI单疗在2L (35.1%) 中是常见的.
对于新的ES-SCLC,ICI加上基于的化疗在1L (64.4%) 中普遍存在,其次是2L (44.9%) 中的其他化疗.
很大一部分患者接受了2L (62.6%-70.3%) 和3L (62.6%-68.5%) 的ICI,如果不接受1L治疗,则有些人接受了ICI重复治疗 (14.5%-50.0%跨线).

结论:

在ES-SCLC中现实世界的ICI利用正在发展,在随后的治疗线上越来越多地使用ICI.
该研究强调了优化ICI测序和重新挑战策略的重大未满足需求.
需要进一步的研究来确定ICI再处理在ES-SCLC管理中的最佳作用和时间.

关键词:

扩散阶段的小细胞肺癌.免疫检查点抑制剂免疫检查点抑制剂现实世界的数据.系统性治疗是一种全身疗法.治疗模式治疗模式

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...